Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma

Nicolas Girard
European Respiratory Journal 2012 39: 1551; DOI: 10.1183/09031936.00042912
Nicolas Girard
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: nicolas.girard@chu-lyon.fr
  • Article
  • Info & Metrics
  • PDF
Loading

From the authors:

We thank P. Mohapatra and co-workers for their interest in our article. Their comments highlight some of the current challenges in predicting response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in lung cancer. We built our nomogram to predict the presence of EGFR activating mutations, as these alterations represent the best available predictive biomarker in this setting, at a time when data about tumour response to EGFR TKIs were not available from large cohorts of patients [1]. Once such data emerge, a predictive model of tumour response to EGFR TKIs, as well as other targeted therapies in other molecular subsets of lung tumours, may be developed.

As we stated, EGFR genotyping is now a standard, and should be obtained when possible. Physicians, as well as healthcare providers, need to work on offering each patient with lung cancer molecular diagnoses, including EGFR mutation genotyping, as well as testing for other oncogenic alterations if specific targeted therapies are available [2]. Despite undeniable progress in recent years, one must keep in mind that molecular diagnoses are not routinely available in numerous countries, including European countries.

Mutation genotyping based on serum tumour DNA or circulating tumour cells is a promising concept, and may be useful when access to tumour tissue is limited [3, 4]. However, such techniques remain to be evaluated and implemented in routine practice, even in developed countries. Of note, the two papers cited by P. Mohapatra and co-workers included only 58 and 35 patients, respectively [3, 4]. Ultimately, the evaluation of such new predictive biomarkers is challenging, and beyond the small experience reported so far, dedicated prospective trials may be required to accurately assess their sensitivity, specificity and positive and negative predictive values.

In the end, nomograms are user-friendly graphical representations of predictive models. Nomograms have been evaluated in specific clinical situations, and subsequently integrated in clinical practice guidelines, especially in prostate cancer [5, 6]. As we discussed in our article, our nomogram, despite its strong accuracy in non-Asian patients, does have some limitations. Any prediction instrument incorporates a certain degree of uncertainty. Although we built our model using an international multicentre cohort of patients, our nomogram needs to be further validated in additional cohorts. Its potential role in individual decision making remains to be determined. Aiming at facilitating subsequent studies, we have developed a website (www.myEGFRscore.com) that, based on our predictive model, provides the individual probability of EGFR mutation in non-Asian patients with lung adenocarcinoma tumours, in an even more straightforward way in routine clinical care.

Footnotes

  • Statement of Interest

    None declared.

  • ©ERS 2012

REFERENCES

  1. ↵
    1. Girard N,
    2. Sima CS,
    3. Jackman DM,
    4. et al
    . Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. Eur Respir J 2012; 39: 366–372.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Pao W,
    2. Girard N
    . New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011; 12: 175–180.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Jiang B,
    2. Liu F,
    3. Yang L,
    4. et al
    . Serum detection of epidermal growth factor receptor gene mutations using mutant-enriched sequencing in Chinese patients with advanced non-small cell lung cancer. J Int Med Res 2011; 39: 1392–1401.
    OpenUrlPubMed
  4. ↵
    1. Yung TK,
    2. Chan KC,
    3. Mok TS,
    4. et al
    . Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 2009; 15: 2076–2084.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Lecuona A,
    2. Heyns CF
    . A prospective, randomized trial comparing the Vienna nomogram to an eight-core prostate biopsy protocol. BJU Int 2011; 108: 204–108.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Susman E,
    2. Phend C
    . Nomograms inserted into NCCN prostate cancer guidelines. Oncology Times 2003; 25: 28–31.
    OpenUrl
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 39 Issue 6 Table of Contents
European Respiratory Journal: 39 (6)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma
Nicolas Girard
European Respiratory Journal Jun 2012, 39 (6) 1551; DOI: 10.1183/09031936.00042912

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma
Nicolas Girard
European Respiratory Journal Jun 2012, 39 (6) 1551; DOI: 10.1183/09031936.00042912
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Footnotes
    • REFERENCES
  • Info & Metrics
  • PDF

Subjects

  • Genetics
  • Lung cancer
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Clinical outcomes of bronchiectasis in India
  • Reply: Clinical outcomes of bronchiectasis in India
  • Risk factors for disease progression in fibrotic hypersensitivity pneumonitis
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society